NASDAQ : OBIO
Orchestra BioMed Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.09 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 366.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 355.22M |
| Enterprise Value | 316.02M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 60.11M |
| Shares Outstanding | 60.11M |
| Shares Change (YoY) | +56.50% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 4.11% |
| Owned by Institutions (%) | 26.85% |
| Float | 32.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.11 |
| Forward PS | 816.09 |
| PB Ratio | 18.38 |
| P/TBV Ratio | 18.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 9.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.26 |
| Quick Ratio | 8.17 |
| Debt / Equity | 2.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.56 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -397.30% |
| Return on Assets (ROA) | -45.73% |
| Return on Invested Capital (ROIC) | -62.05% |
| Return on Capital Employed (ROCE) | -56.73% |
| Weighted Average Cost of Capital (WACC) | 6.93% |
| Revenue Per Employee | $371,814 |
| Profits Per Employee | -$692,698 |
| Employee Count | 86 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 0.72 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +63.71% |
| 50-Day Moving Average | 5.70 |
| 200-Day Moving Average | 4.53 |
| Relative Strength Index (RSI) | 53.59 |
| Average Volume (20 Days) | 325,809 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.55M |
| Short Previous Month | 2.55M |
| Short % of Shares Out | 4.25% |
| Short % of Float | 7.75% |
| Short Ratio (days to cover) | 8.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 31.98M |
| Gross Profit | 31.82M |
| Operating Income | -57.99M |
| Pretax Income | -59.03M |
| Net Income | -59.57M |
| EBITDA | -57.64M |
| EBIT | -57.99M |
| Loss Per Share | -$1.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 109.96M |
| Total Debt | 70.76M |
| Net Cash | 39.20M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 29.42M |
| Book Value Per Share | 0.32 |
| Working Capital | 97.77M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -58.32M |
| Capital Expenditures | -781,000 |
| Depreciation & Amortization | 349,000 |
| Net Borrowing | 55.00M |
| Free Cash Flow | -59.10M |
| FCF Per Share | -$0.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | 99.51% |
| Operating Margin | -181.36% |
| Pretax Margin | -184.60% |
| Profit Margin | -184.60% |
| EBITDA Margin | -180.27% |
| EBIT Margin | -181.36% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -56.50% |
| Shareholder Yield | -56.50% |
| Earnings Yield | -16.91% |
| FCF Yield | -16.64% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.43 |
| Price Target Difference | 110.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -25.43% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.83 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |